Benzinga
Benzinga
Benzinga
lunes, septiembre 28

Wave Life Sciences Inc

WVENASDAQ
Trade with Public
Trade with Public
$3.78
-0.18-4.55%
al cierre: Sep 24, 5:00 PM EST
$3.71
-0.25-6.31%
Premercado: 5:23 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Wave Life Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Wave Life Sciences (WVE).

Price Target Range — 12 Quarters

Analyst Consensus — 18 Analysts

17Buy
1Hold
Consensus RatingBuy# Analysts18Avg. Consensus PT$23Upside to Avg. PT+524.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →
DateFirmAnalystActionRating ChangePrice Target
Sep 23, 2026JP MorganTessa RomeroDowngradeOverweight→Neutral—
Aug 4, 2026MizuhoSalim SyedPT CutOutperform$27→$23
More with Benzinga EdgeGet Access

Analyst Ratings News

This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Wall Street analysts downgraded Rollins, Yum Brands, Alkami Technology, VICI Properties and Safehold, cutting targets for Rollins and Alkami.
Avi Kapoor

This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.
Avi Kapoor

PRO
JP Morgan Downgrades Wave Life Sciences to Neutral

JP Morgan analyst Tessa Romero downgrades Wave Life Sciences (NASDAQ:WVE) from Overweight to Neutral.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $23

Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers the price target from $27 to $23.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on WAVE Life Sciences, Lowers Price Target to $19

Citigroup analyst Samantha Semenkow maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $24 to $19.
Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on WAVE Life Sciences, Lowers Price Target to $22

B. Riley Securities analyst Madison El-Saadi maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $31 to $22.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved